共 50 条
- [1] Safety, efficacy, and biomarker results from an open-label, multicenter, phase 1 study of RP2 alone or combined with nivolumab in a cohort of patients with uveal melanomaJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Sacco, Joseph J.Harrington, Kevin JosephOlsson-Brown, AnnaChan, Tze Y.Nenclares, PabloLeslie, IslaBommareddy, PraveenKalbasi, AlirezaXie, BenMishal, MoranCohan, David MichaelSkolariki, AglaiaMiddleton, Mark R.
- [2] An open-label, multicenter, phase I study of RP2 as a single agent and in combination with nivolumab in patients with solid tumors: Safety, efficacy, and biomarker resultsANNALS OF ONCOLOGY, 2022, 33 (07) : S926 - S927Harrington, K. J.Sacco, J. J.Olsson-Brown, A.Chan, T.Nenclares, P.Leslie, I.Bommareddy, P.Ahlers, C.Wolff, J.Middleton, M. R.
- [3] An open-label, multicenter, phase 1 study of RP3 as a single agent and in combination with nivolumab in patients (pts) with solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Harrington, Kevin JosephRullan, AntonioDeighton, LouiseBarata, JoaoCastro, HenryAhlers, Christoph MatthiasMcrae, JohnBommareddy, PraveenCoffin, Robert S.Middleton, Mark R.
- [4] An open-label, multicenter, phase I/II clinical trial of RP1 as a single agent and in combination with nivolumab in patients with solid tumors [IGNYTE]ANNALS OF ONCOLOGY, 2021, 32 : S903 - S904Aroldi, F.Middleton, M. R.Sacco, J. J.Milhem, M. M.Curti, B. D.VanderWalde, A. M.Baum, S. L.Samson, A.Chesney, J.Niu, J.Rhodes, T. D.Bowles, T. L.Olsson-Brown, A.Laux, D. E.Bommareddy, P. K.Menezes, L.Samakoglu, S.Pirzkall, A.Coffin, R. S.Harrington, K. J.
- [5] Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 StudyANNALS OF SURGICAL ONCOLOGY, 2024, 31 (08) : 5340 - 5351Zager, Jonathan S.Orloff, MarlanaFerrucci, Pier FrancescoChoi, JunsungEschelman, David J.Glazer, Evan S.Ejaz, AslamHoward, J. HarrisonRichtig, ErikaOchsenreither, SebastianReddy, Sunil A.Lowe, Michael C.Beasley, Georgia M.Gesierich, AnjaBender, ArminGschnell, MartinDummer, ReinhardRivoire, MichelArance, AnaFenwick, Stephen WilliamSacco, Joseph J.Haferkamp, SebastianWeishaupt, CarstenJohn, JohnnyWheater, MatthewOttensmeier, Christian H.
- [6] Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II studyEUROPEAN JOURNAL OF CANCER, 2018, 105 : 114 - 126Namikawa, KenjiroKiyohara, YoshioTakenouchi, TatsuyaUhara, HisashiUchi, HiroshiYoshikawa, ShusukeTakatsuka, SumikoKoga, HiroshiWada, NaokoMinami, HironobuHatsumichi, MasahiroAsada, SuguruNamba, YoshinobuYamazaki, Naoya
- [7] ASO Visual Abstract: Efficacy and Safety of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter, Phase 3 StudyANNALS OF SURGICAL ONCOLOGY, 2024, 31 (08) : 5220 - 5221Zager, Jonathan S.Orloff, MarlanaFerrucci, Pier FrancescoChoi, JunsungEschelman, David J.Glazer, Evan S.Ejaz, AslamHoward, J. HarrisonRichtig, ErikaOchsenreither, SebastianReddy, Sunil A.Lowe, Michael C.Beasley, Georgia M.Gesierich, AnjaBender, ArminGschnell, MartinDummer, ReinhardRivoire, MichelArance, AnaFenwick, Stephen WilliamSacco, Joseph J.Haferkamp, SebastianWeishaupt, CarstenJohn, JohnnyWheater, MatthewOttensmeier, Christian H.
- [8] Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma.JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Atkins, Michael B.Reiney, RaginiSznol, Kudchadkar MarioMcDermott, David F.Lotem, MichalSchachter, JacobWolchok, Jedd D.Urba, Walter JohnKuzel, TimothySchuchter, Lynn MaraSlingluff, Craig L.Ernstoff, Marc S.Fay, Joseph W.Friedlander, Philip AdamGajewski, ThomasZarour, Hassane M.Rotem-Yehudar, RinatSosman, Jeffrey Alan
- [9] Pharmacokinetics, Pharmacodynamics, and Safety of Nivolumab in Patients With Sepsis-Induced Immunosuppression: A Multicenter, Open-Label Phase 1/2 StudySHOCK, 2020, 53 (06): : 686 - 694Watanabe, EizoNishida, OsamuKakihana, YasuyukiOdani, MotoiOkamura, TatsuakiHarada, TomohiroOda, Shigeto
- [10] Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT)CLINICAL CANCER RESEARCH, 2019, 25 (18) : 5485 - 5492Okada, MorihitoKijima, TakashiAoe, KeisukeKato, TerufumiFujimoto, NobukazuNakagawa, KazuhikoTakeda, YuichiroHida, ToyoakiKanai, KuninobuImamura, FumioOizumi, SatoshiTakahashi, ToshiakiTakenoyama, MitsuhiroTanaka, HiroshiHirano, JunNamba, YoshinobuOhe, Yuichiro